Continuous photoacoustic monitoring of neonatal stroke in intensive care unit

Ended Project Grant Awarded Last action

Award ID
R41EB033758
Recipient
Awarding agency
Obligated
$688,936

Award facts

Completion date
Originally
Place of performance
Maryland, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
Neonatal encephalopathy can arise from fetal hypoxia-ischemia during labor, chronic uteroplacental inflammation, and large cerebral artery embolization primarily arising from dislodgement of a placental thrombus. Because of overlapping clinical presentation, differential diagnosis is often delayed until seizures develop and MRI can be safely performed, a time at which most neuroprotectants are ineffective. Whereas hypothermia is approved for use within 6 hours of birth for hypoxia-ischemia, no treatments have been approved for perinatal arterial ischemic stroke because of the difficulty of definitive diagnosis required for clinical trial stratification at birth. With an estimated incidence of 17-93 per 100,000 live births, the incidence of stroke in the perinatal period rivals the incidence of stroke in adults (17-23 per 100,000). Therefore, a device that could rapidly and reliably identify an area of focal cerebral ischemia soon after birth would have a major impact by enabling the testing of neuroprotectants at an early therapeutic time window that would maximize efficacy. The brimrose technology corporation, partnering with johns hopkins university, propose a photoacoustic helmet (PAH) device that can be safely deployed at the bedside in the neonatal intensive care unit to 1) continuously monitor and rapidly identify at-risk neonates, shortly after birth, rapidly allowing them to be triaged to therapy; 2) monitor the progress of therapy; and 3) provide prognostic information to the parents of newborns at risk for life-long brain injury. The PA imaging mechanism is a purely hybrid mechanism, providing rich optical absorbance contrast of tissue OXY- and deoxyhemoglobin through intact scalp and skull. A proof-of-concept of detecting decreased tissue oxyhemoglobin in a 1 CM-induced experimental stroke has been demonstrated with standard laboratory PA laser light source and clinical ultrasound detector. Our goal is to incorporate safer light-emitting diodes (leds) and more sensitive ultrasound detectors configured in a neonatal helmet to localize cortical regions of low oxygenation in the newborn. In the proposed phase-i sttr, we will develop fundamental hardware and software components for effective integration. Aim 1 - software for safe PAH imaging at high contrast resolution, including deep neural network and optimal spectral unmixing techniques to enable a safe and high-speed led-based PAH system. Aim 2 - hardware for modular PAH system, including a fiber-coupled brimrose ultra-sensitive multi- bounce laser microphone and optimal modular unit design for a PAH imaging at high spatial-temporal-spectral resolution through intact scalp and skull. Aim 3 - framework for modular PAH system integration, enabling a robust integration of modular units in a PAH system with rigid-body tag registration using optical tracking, in which different neonatal head shapes and need for different imaging specifications can be accommodated. The phase-i milestone is detection of the full blood O2 saturation range at

Transactions

Action Obligated Date
Amendment $0
Amendment $344,468
Original award $344,468

Quick answers

Who received award R41EB033758?

R41EB033758 was awarded to Brimrose Technology Corp by National Institute of Biomedical Imaging and Bioenginering (National Institutes of Health) on September 2, 2022.

How much is award R41EB033758 worth?

$688,936 has been obligated on R41EB033758.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login